Clostridioides difficile recurrence in individuals with and without cancer: a Swedish population-based cohort study.
Clostridioides difficile
Cancer
Epidemiology
Real World Evidence
Recurrence
Risk factors
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
received:
08
12
2023
accepted:
19
01
2024
pubmed:
26
2
2024
medline:
26
2
2024
entrez:
26
2
2024
Statut:
ppublish
Résumé
Patients with cancer are vulnerable to Clostridioides difficile infection (CDI) due to their disease, treatment and regular hospital contact, yet if CDI-recurrence is more common remains unclear, and differences among cancer types remain unexplored. This Swedish nationwide population-based cohort included all 43,150 individuals with recorded CDI (2006-2019) to assess CDI-recurrence in individuals with and without cancer, with binary multivariable logistic regression, stratified by anatomical location, and survival status. Compared to those without cancer (N = 29,543), ongoing cancer (diagnosis < 12 months; N = 3,882) was associated with reduced recurrence (OR = 0.81, 95% CI 0.73-0.89), while there was no association with cancer history (diagnosis ≥ 12 months; N = 9,725). There was an increased 8-week all-cause mortality (Ongoing cancer: OR = 1.58, 95% CI 1.43-1.74; Cancer history: OR = 1.45, 95% CI 1.36-1.55) compared to those without cancer. Among CDI-survivors, those with ongoing cancer presented with a decreased odds of recurrence (OR = 0.84, 95% CI 0.76-0.94), compared to those without cancer history, with no association for those with cancer history (OR = 1.04, 95% CI 0.97-1.1). Large variations were seen across cancer types, with the highest observed proportion of recurrence in oral and mesothelial cancer, and the lowest for esophageal cancer, although no statistically significant OR were found. The population-based study indicates that individuals with cancer may have fewerrecurrences than expected, yet variations by cancer type were large, and mortality was high.
Identifiants
pubmed: 38407777
doi: 10.1007/s15010-024-02193-1
pii: 10.1007/s15010-024-02193-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
649-660Subventions
Organisme : Vetenskapsrådet
ID : 2020-01058
Informations de copyright
© 2024. The Author(s).
Références
Seekatz AM, Safdar N, Khanna S. The role of the gut microbiome in colonization resistance and recurrent Clostridioides difficile infection. Ther Adv Gastroenterol. 2022;15:17562848221134396. https://doi.org/10.1177/17562848221134396 .
doi: 10.1177/17562848221134396
Sehgal K, Khanna S. Gut microbiome and Clostridioides difficile infection: a closer look at the microscopic interface. Therap Adv Gastroenterol. 2021;14:1756284821994736. https://doi.org/10.1177/1756284821994736 .
doi: 10.1177/1756284821994736
pubmed: 33747125
pmcid: 7905718
Cold F, Svensson CK, Petersen AM, Hansen LH, Helms M. Long-term safety following faecal microbiota transplantation as a treatment for recurrent Clostridioides difficile infection compared with patients treated with a fixed bacterial mixture: results from a retrospective cohort study. Cells. 2022. https://doi.org/10.3390/cells11030435 .
doi: 10.3390/cells11030435
pubmed: 36291139
pmcid: 9600246
Soveral LF, Korczaguin GG, Schmidt PS, Nunes IS, Fernandes C, Zárate-Bladés CR. Immunological mechanisms of fecal microbiota transplantation in recurrent Clostridioides difficile infection. World J Gastroenterol. 2022;28:4762–72. https://doi.org/10.3748/wjg.v28.i33.4762 .
doi: 10.3748/wjg.v28.i33.4762
pubmed: 36156924
pmcid: 9476857
Khan I, Bai Y, Zha L, Ullah N, Ullah H, Shah SRH, et al. Mechanism of the gut microbiota colonization resistance and enteric pathogen infection. Front Cell Infect Microbiol. 2021. https://doi.org/10.3389/fcimb.2021.716299 .
doi: 10.3389/fcimb.2021.716299
pubmed: 35047421
pmcid: 8733563
Chilton CH, Pickering DS, Freeman J. Microbiologic factors affecting Clostridium difficile recurrence. Clin Microbiol Infect. 2018;24:476–82. https://doi.org/10.1016/j.cmi.2017.11.017 .
doi: 10.1016/j.cmi.2017.11.017
pubmed: 29208562
Aziz M, Fatima R, Douglass LN, Abughanimeh O, Raza S. Current updates in management of Clostridium difficile infection in cancer patients. Curr Med Res Opin. 2019;35:473–8. https://doi.org/10.1080/03007995.2018.1487389 .
doi: 10.1080/03007995.2018.1487389
pubmed: 29888965
Edwards PT, Thurm CW, Hall M, Busing JD, Kahn SA, Kellermayer R, et al. Clostridioides difficile infection in hospitalized pediatric patients: Comparisons of epidemiology, testing, and treatment from 2013 to 2019. J Pediatr. 2022. https://doi.org/10.1016/j.jpeds.2022.08.030 .
doi: 10.1016/j.jpeds.2022.08.030
pubmed: 36181871
pmcid: 9771922
Finn E, Andersson FL, Madin-Warburton M. Burden of Clostridioides difficile infection (CDI)—a systematic review of the epidemiology of primary and recurrent CDI. BMC Infect Dis. 2021;21:456. https://doi.org/10.1186/s12879-021-06147-y .
doi: 10.1186/s12879-021-06147-y
pubmed: 34016040
pmcid: 8135979
Fu Y, Luo Y, Grinspan AM. Epidemiology of community-acquired and recurrent Clostridioides difficile infection. Therap Adv Gastroenterol. 2021;14:17562848211016248. https://doi.org/10.1177/17562848211016248 .
doi: 10.1177/17562848211016248
pubmed: 34093740
pmcid: 8141977
Marra AR, Perencevich EN, Nelson RE, Samore M, Khader K, Chiang HY, et al. Incidence and outcomes associated with Clostridium difficile infections: a systematic review and meta-analysis. JAMA Netw Open. 2020;3: e1917597. https://doi.org/10.1001/jamanetworkopen.2019.17597 .
doi: 10.1001/jamanetworkopen.2019.17597
pubmed: 31913488
pmcid: 6991241
Milenković B, Šuljagić V, Perić A, Dragojević-Simić V, Tarabar O, Milanović M, et al. Outcomes of Clostridioides difficile infection in adult cancer and non-cancer patients hospitalised in a tertiary hospital: a prospective cohort study. Eur J Hosp Pharm. 2022;29:e15–22. https://doi.org/10.1136/ejhpharm-2020-002574 .
doi: 10.1136/ejhpharm-2020-002574
pubmed: 33579720
Balsells E, Shi T, Leese C, Lyell I, Burrows J, Wiuff C, et al. Global burden of Clostridium difficile infections: a systematic review and meta-analysis. J Glob Health. 2019;9:010407. https://doi.org/10.7189/jogh.09.010407 .
doi: 10.7189/jogh.09.010407
pubmed: 30603078
Deshpande A, Pasupuleti V, Thota P, Pant C, Rolston DD, Hernandez AV, et al. Risk factors for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2015;36:452–60. https://doi.org/10.1017/ice.2014.88 .
doi: 10.1017/ice.2014.88
pubmed: 25626326
Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect. 2008;70:298–304. https://doi.org/10.1016/j.jhin.2008.08.012 .
doi: 10.1016/j.jhin.2008.08.012
pubmed: 18951661
Abou Chakra CN, Pepin J, Sirard S, Valiquette L. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PLoS ONE. 2014;9: e98400. https://doi.org/10.1371/journal.pone.0098400 .
doi: 10.1371/journal.pone.0098400
pubmed: 24897375
pmcid: 4045753
Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. Int J Antimicrob Agents. 2016;48:1–10. https://doi.org/10.1016/j.ijantimicag.2016.03.008 .
doi: 10.1016/j.ijantimicag.2016.03.008
pubmed: 27216385
Trifan A, Stanciu C, Girleanu I, Stoica OC, Singeap AM, Maxim R, et al. Proton pump inhibitors therapy and risk of Clostridium difficile infection: systematic review and meta-analysis. World J Gastroenterol. 2017;23:6500–15. https://doi.org/10.3748/wjg.v23.i35.6500 .
doi: 10.3748/wjg.v23.i35.6500
pubmed: 29085200
pmcid: 5643276
Slimings C, Riley TV. Antibiotics and healthcare facility-associated Clostridioides difficile infection: systematic review and meta-analysis 2020 update. J Antimicrob Chemother. 2021;76:1676–88. https://doi.org/10.1093/jac/dkab091 .
doi: 10.1093/jac/dkab091
pubmed: 33787887
Cao F, Chen CX, Wang M, Liao HR, Wang MX, Hua SZ, et al. Updated meta-analysis of controlled observational studies: proton-pump inhibitors and risk of Clostridium difficile infection. J Hosp Infect. 2018;98:4–13. https://doi.org/10.1016/j.jhin.2017.08.017 .
doi: 10.1016/j.jhin.2017.08.017
pubmed: 28842261
Tariq R, Singh S, Gupta A, Pardi DS, Khanna S. Association of gastric acid suppression with recurrent Clostridium difficile infection: a systematic review and meta-analysis. JAMA Intern Med. 2017;177:784–91. https://doi.org/10.1001/jamainternmed.2017.0212 .
doi: 10.1001/jamainternmed.2017.0212
pubmed: 28346595
pmcid: 5540201
Mehta P, Nahass RG, Brunetti L. Acid suppression Medications during hospitalization as a risk factor for recurrence of Clostridioides difficile infection: systematic review and meta-analysis. Clin Infect Dis. 2021;73:e62–8. https://doi.org/10.1093/cid/ciaa545 .
doi: 10.1093/cid/ciaa545
pubmed: 32386313
D’Silva KM, Mehta R, Mitchell M, Lee TC, Singhal V, Wilson MG, et al. Proton pump inhibitor use and risk for recurrent Clostridioides difficile infection: a systematic review and meta-analysis. Clin Microbiol Infect. 2021. https://doi.org/10.1016/j.cmi.2021.01.008 .
doi: 10.1016/j.cmi.2021.01.008
pubmed: 33465501
Yepez Guevara EA, Aitken SL, Olvera AV, Carlin L, Fernandes KE, Bhatti MM, et al. Clostridioides difficile infection in cancer and immunocompromised patients: relevance of a two-step diagnostic algorithm and infecting Ribotypes on clinical outcomes. Clin infect dis. 2021;72:e460–5. https://doi.org/10.1093/cid/ciaa1184 .
doi: 10.1093/cid/ciaa1184
pubmed: 32803229
Neemann K, Freifeld A. Clostridium difficile–associated diarrhea in the oncology patient. J Oncol Pract. 2017;13:25–30. https://doi.org/10.1200/jop.2016.018614 .
doi: 10.1200/jop.2016.018614
pubmed: 28084880
Hebbard AI, Slavin MA, Reed C, Teh BW, Thursky KA, Trubiano JA, et al. The epidemiology of Clostridium difficile infection in patients with cancer. Expert Rev Anti Infect Ther. 2016;14:1077–85. https://doi.org/10.1080/14787210.2016.1234376 .
doi: 10.1080/14787210.2016.1234376
pubmed: 27606976
Abughanimeh O, Qasrawi A, Kaddourah O, Al Momani L, Abu Ghanimeh M. Clostridium difficile infection in oncology patients: epidemiology, pathophysiology, risk factors, diagnosis, and treatment. Hosp Pract (1995). 2018;46:266–77. https://doi.org/10.1080/21548331.2018.1533673 .
doi: 10.1080/21548331.2018.1533673
pubmed: 30296190
Appaneal HJ, Caffrey AR, Beganovic M, Avramovic S, LaPlante KL. Predictors of Clostridioides difficile recurrence across a national cohort of veterans in outpatient, acute, and long-term care settings. Am J Health-Syst Pharm AJHP. 2019;76:581–90. https://doi.org/10.1093/ajhp/zxz032 .
doi: 10.1093/ajhp/zxz032
pubmed: 31361830
Hikone M, Ainoda Y, Tago S, Fujita T, Hirai Y, Takeuchi K, et al. Risk factors for recurrent hospital-acquired Clostridium difficile infection in a Japanese university hospital. Clin Exp Gastroenterol. 2015;8:191–6. https://doi.org/10.2147/ceg.s85007 .
doi: 10.2147/ceg.s85007
pubmed: 26203270
pmcid: 4507450
Negrut N, Bungau S, Behl T, Khan SA, Vesa CM, Bustea C, et al. Risk factors associated with recurrent Clostridioides difficile infection. Healthcare. 2020;8:352.
doi: 10.3390/healthcare8030352
pubmed: 32967323
pmcid: 7551610
Mikamo H, Kondo T, Okuyama K, Marcella SW, Ruzicka DJ. Incidence of and risk factors for recurrent Clostridioidesdifficile infection in Japan using a claims database: a retrospective cohort study. Anaerobe. 2020;61:102139. https://doi.org/10.1016/j.anaerobe.2019.102139 .
doi: 10.1016/j.anaerobe.2019.102139
pubmed: 31830597
Kimura T, Snijder R, Sugitani T. Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: a nationwide real-world analysis using a large hospital-based administrative dataset. J Infect Chemother. 2019;25:615–20. https://doi.org/10.1016/j.jiac.2019.03.011 .
doi: 10.1016/j.jiac.2019.03.011
pubmed: 30987950
Dharbhamulla N, Abdelhady A, Domadia M, Patel S, Gaughan J, Roy S. Risk factors associated with recurrent Clostridium difficile Infection. J Clin Med Res. 2019;11:1–6. https://doi.org/10.14740/jocmr3531w .
doi: 10.14740/jocmr3531w
pubmed: 30627271
Song JH, Kim YS. Recurrent Clostridium difficile infection: risk factors, treatment, and prevention. Gut and liver. 2019;13:16–24. https://doi.org/10.5009/gnl18071 .
doi: 10.5009/gnl18071
pubmed: 30400734
Durovic A, Widmer AF, Frei R, Tschudin-Sutter S. Distinguishing Clostridium difficile recurrence from reinfection: independent validation of current recommendations. Infect Control Hosp Epidemiol. 2017;38:891–6. https://doi.org/10.1017/ice.2017.119 .
doi: 10.1017/ice.2017.119
pubmed: 28592348
Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450. https://doi.org/10.1186/1471-2458-11-450 .
doi: 10.1186/1471-2458-11-450
pubmed: 21658213
pmcid: 3142234
Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish prescribed drug Register–opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16:726–35. https://doi.org/10.1002/pds.1294 .
doi: 10.1002/pds.1294
pubmed: 16897791
Barlow L, Westergren K, Holmberg L, Talback M. The completeness of the Swedish cancer register: a sample survey for year 1998. Acta Oncol. 2009;48:27–33. https://doi.org/10.1080/02841860802247664 .
doi: 10.1080/02841860802247664
pubmed: 18767000
Brooke HL, Talbäck M, Hörnblad J, Johansson LA, Ludvigsson JF, Druid H, et al. The Swedish cause of death register. Eur J Epidemiol. 2017;32:765–73. https://doi.org/10.1007/s10654-017-0316-1 .
doi: 10.1007/s10654-017-0316-1
pubmed: 28983736
pmcid: 5662659
Boven A, Vlieghe E, Engstrand L, Andersson FL, Callens S, Simin J, et al. Clostridioides difficile infection-associated cause-specific and all-cause mortality: a population-based cohort study. Clin Microbiol Infect. 2023. https://doi.org/10.1016/j.cmi.2023.07.008 .
doi: 10.1016/j.cmi.2023.07.008
pubmed: 37473840
Moreels N, Boven A, Gressani O, Andersson F, Vlieghe E, Callens S, et al. The combined effect of systemic antibiotics and proton pump inhibitors on Clostridioides difficile infection and recurrence. J Antimicrob Chemother. 2024. https://doi.org/10.1093/jac/dkae012 .
doi: 10.1093/jac/dkae012
pubmed: 38267263
pmcid: 10904719
Boven A, Simin J, Andersson F, Vlieghe E, Callens S, Zeebari Z, et al. Clostridioides difficile infection and recurrence and the associated healthcare consumption in Sweden. Clin Microbiol Infect. 2023. https://doi.org/10.1016/j.cmi.2023.07.008 .
doi: 10.1016/j.cmi.2023.07.008
pubmed: 37473840
Wong SK, Hamm J, Shokoohi A, McGahan CE, Ho C. Real world duration of curative intent breast, colorectal, non-small cell lung, and prostate cancer treatment. BMC Cancer. 2021;21:215. https://doi.org/10.1186/s12885-021-07923-4 .
doi: 10.1186/s12885-021-07923-4
pubmed: 33653306
pmcid: 7923613
Brusselaers N, Lagergren J. The Charlson comorbidity index in registry-based research. Methods Inf Med. 2017;56:401–6. https://doi.org/10.3414/ME17-01-0051 .
doi: 10.3414/ME17-01-0051
pubmed: 29582935
Ludvigsson JF, Appelros P, Askling J, Byberg L, Carrero JJ, Ekstrom AM, et al. Adaptation of the Charlson comorbidity index for register-based research in Sweden. Clin Epidemiol. 2021;13:21–41. https://doi.org/10.2147/CLEP.S282475 .
doi: 10.2147/CLEP.S282475
pubmed: 33469380
pmcid: 7812935
Brusselaers N. Prescribed drugs and the microbiome. Gastroenterol Clin North Am. 2019;48:331–42. https://doi.org/10.1016/j.gtc.2019.04.002 .
doi: 10.1016/j.gtc.2019.04.002
pubmed: 31383274
Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133:601–9. https://doi.org/10.1161/CIRCULATIONAHA.115.017719 .
doi: 10.1161/CIRCULATIONAHA.115.017719
pubmed: 26858290
pmcid: 4741409
Coemans M, Verbeke G, Dohler B, Susal C, Naesens M. Bias by censoring for competing events in survival analysis. BMJ. 2022;378: e071349. https://doi.org/10.1136/bmj-2022-071349 .
doi: 10.1136/bmj-2022-071349
pubmed: 36100269
van Geloven N, Steyerberg E, Putter H. Competing events: avoiding censoring is too simple an answer. BMJ. 2022;378: e071349.
Chung MS, Kim J, Kang JO, Pai H. Impact of malignancy on Clostridium difficile infection. Eur J Clin micr obial in fect Dis. 2016;35:1771–6. https://doi.org/10.1007/s10096-016-2725-6 .
doi: 10.1007/s10096-016-2725-6
Abu-Sbeih H, Choi K, Tran CN, Wang X, Lum P, Shuttlesworth G, et al. Recurrent Clostridium difficile infection is associated with treatment failure and prolonged illness in cancer patients. Eur J Gastroenterol Hepatol. 2019;31:128–34. https://doi.org/10.1097/MEG.0000000000001288 .
doi: 10.1097/MEG.0000000000001288
pubmed: 30339561
Delgado A, Reveles IA, Cabello FT, Reveles KR. Poorer outcomes among cancer patients diagnosed with Clostridium difficile infections in United States community hospitals. BMC Infect Dis. 2017;17:448. https://doi.org/10.1186/s12879-017-2553-z .
doi: 10.1186/s12879-017-2553-z
pubmed: 28645266
pmcid: 5481960
Calbo E, Hernández S, Sopena N, Castellá L, Lopez-Contreras J, Cuquet J, et al. Late poor outcomes of Clostridioides difficile infections in oncological patients: a multicentre cohort study. J Infect Prev. 2023;24:182–6. https://doi.org/10.1177/17571774231165410 .
doi: 10.1177/17571774231165410
pubmed: 37333870
Mansournia MA, Nazemipour M, Etminan M. A practical guide to handling competing events in etiologic time-to-event studies. Glob Epidemiol. 2022;4:100080. https://doi.org/10.1016/j.gloepi.2022.100080 .
doi: 10.1016/j.gloepi.2022.100080
pubmed: 37637022
pmcid: 10446108
Seekatz AM, Rao K, Santhosh K, Young VB. Dynamics of the fecal microbiome in patients with recurrent and nonrecurrent Clostridium difficile infection. Genome Med. 2016;8:47. https://doi.org/10.1186/s13073-016-0298-8 .
doi: 10.1186/s13073-016-0298-8
pubmed: 27121861
pmcid: 4847246
Allegretti JR, Kearney S, Li N, Bogart E, Bullock K, Gerber GK, et al. Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles. Aliment Pharmacol Ther. 2016;43:1142–53. https://doi.org/10.1111/apt.13616 .
doi: 10.1111/apt.13616
pubmed: 27086647
pmcid: 5214573
Almeida R, Gerbaba T, Petrof EO. Recurrent Clostridium difficile infection and the microbiome. J Gastroenterol. 2016;51:1–10. https://doi.org/10.1007/s00535-015-1099-3 .
doi: 10.1007/s00535-015-1099-3
pubmed: 26153514
Khanna S, Montassier E, Schmidt B, Patel R, Knights D, Pardi DS, et al. Gut microbiome predictors of treatment response and recurrence in primary Clostridium difficile infection. Aliment Pharmacol Ther. 2016;44:715–27. https://doi.org/10.1111/apt.13750 .
doi: 10.1111/apt.13750
pubmed: 27481036
pmcid: 5012905
Meza-Torres J, Auria E, Dupuy B, Tremblay YDN. Wolf in sheep’s clothing: Clostridioides difficile biofilm as a reservoir for recurrent infections. Microorganisms. 2021. https://doi.org/10.3390/microorganisms9091922 .
doi: 10.3390/microorganisms9091922
pubmed: 34576818
pmcid: 8470499
Normington C, Moura IB, Bryant JA, Ewin DJ, Clark EV, Kettle MJ, et al. Biofilms harbour Clostridioides difficile, serving as a reservoir for recurrent infection. NPJ Biofilms Microbiomes. 2021;7:16. https://doi.org/10.1038/s41522-021-00184-w .
doi: 10.1038/s41522-021-00184-w
pubmed: 33547298
pmcid: 7864922
Merchant R, Mower WR, Ourian A, Abrahamian FM, Moran GJ, Krishnadasan A, et al. Association between appendectomy and Clostridium difficile infection. J Clin Med Res. 2012;4:17–9. https://doi.org/10.4021/jocmr770w .
doi: 10.4021/jocmr770w
pubmed: 22383922
pmcid: 3279496
Essrani R, Saturno D, Mehershahi S, Essrani RK, Hossain MR, Ravi SJK, et al. The impact of appendectomy in Clostridium difficile infection and length of hospital stay. Cureus. 2020;12: e10342. https://doi.org/10.7759/cureus.10342 .
doi: 10.7759/cureus.10342
pubmed: 33062466
pmcid: 7549846
Cho J, Cunningham S, Pu M, Lennon RJ, Dens Higano J, Jeraldo P, et al. Clostridioides difficile whole-genome sequencing differentiates relapse with the same strain from reinfection with a new strain. Clin Infect Dis. 2021;72:806–13. https://doi.org/10.1093/cid/ciaa159 .
doi: 10.1093/cid/ciaa159
pubmed: 32064535
Gomez S, Chaves F, Orellana MA. Clinical, epidemiological and microbiological characteristics of relapse and re-infection in Clostridium difficile infection. Anaerobe. 2017;48:147–51. https://doi.org/10.1016/j.anaerobe.2017.08.012 .
doi: 10.1016/j.anaerobe.2017.08.012
pubmed: 28830842
Yano Y, Etemadi A, Abnet CC. Microbiome and cancers of the Esophagus: a review. Microorganisms. 2021;9:1764.
doi: 10.3390/microorganisms9081764
pubmed: 34442842
pmcid: 8398938
Lissoni A, Agliardi E, Peri A, Marchioni R, Abati S. Oral microbiome and mucosal trauma as risk factors for oral cancer: beyond alcohol and tobacco A. literature review. J Biol Regul Homeost Agents. 2020;34:11–8.
pubmed: 33386052
Chattopadhyay I, Verma M, Panda M. Role of oral microbiome signatures in diagnosis and prognosis of oral cancer. Technol Cancer Res Treat. 2019;18:1533033819867354. https://doi.org/10.1177/1533033819867354 .
doi: 10.1177/1533033819867354
pubmed: 31370775
pmcid: 6676258
Rogers MA, Greene MT, Saint S, Chenoweth CE, Malani PN, Trivedi I, et al. Higher rates of Clostridium difficile infection among smokers. PLoS ONE. 2012;7: e42091. https://doi.org/10.1371/journal.pone.0042091 .
doi: 10.1371/journal.pone.0042091
pubmed: 22848714
pmcid: 3407081
Barker AK, Van Galen A, Sethi AK, Shirley D, Safdar N. Tobacco use as a screener for Clostridium difficile infection outcomes. J Hosp Infect. 2018;98:36–9. https://doi.org/10.1016/j.jhin.2017.06.026 .
doi: 10.1016/j.jhin.2017.06.026
pubmed: 28655511
Figueroa I, Johnson S, Sambol SP, Goldstein EJ, Citron DM, Gerding DN. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis. 2012;55:S104–9. https://doi.org/10.1093/cid/cis357 .
doi: 10.1093/cid/cis357
pubmed: 22752857
pmcid: 3388025
Wilcox MH, Fawley WN, Settle CD, Davidson A. Recurrence of symptoms in Clostridium difficile infection–relapse or reinfection? J Hosp Infect. 1998;38:93–100. https://doi.org/10.1016/s0195-6701(98)90062-7 .
doi: 10.1016/s0195-6701(98)90062-7
pubmed: 9522287
Zeng Z, Zhao H, Dorr MB, Shen J, Wilcox MH, Poxton IR, et al. Bezlotoxumab for prevention of Clostridium difficile infection recurrence: distinguishing relapse from reinfection with whole genome sequencing. Anaerobe. 2020;61:102137. https://doi.org/10.1016/j.anaerobe.2019.102137 .
doi: 10.1016/j.anaerobe.2019.102137
pubmed: 31846705
Barker AK, Ngam C, Musuuza JS, Vaughn VM, Safdar N. Reducing Clostridium difficile in the inpatient setting: a systematic review of the adherence to and effectiveness of C. difficile prevention bundles. Infect Control Hosp Epidemiol. 2017;38:639–50. https://doi.org/10.1017/ice.2017.7 .
doi: 10.1017/ice.2017.7
pubmed: 28343455
pmcid: 5654380
Watson RL, Graber CJ. Lack of improvement in antimicrobial prescribing after a diagnosis of Clostridium difficile and impact on recurrence. Am J Infect Control. 2018;46:1370–4. https://doi.org/10.1016/j.ajic.2018.04.213 .
doi: 10.1016/j.ajic.2018.04.213
pubmed: 29779687
Baur D, Gladstone BP, Burkert F, Carrara E, Foschi F, Dobele S, et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17:990–1001. https://doi.org/10.1016/s1473-3099(17)30325-0 .
doi: 10.1016/s1473-3099(17)30325-0
pubmed: 28629876
Paschos P, Ioakim K, Malandris K, Koukoufiki A, Nayfeh T, Akriviadis E, et al. Add-on interventions for the prevention of recurrent Clostridioides difficile infection: a systematic review and network meta-analysis. Anaerobe. 2021;71:102441. https://doi.org/10.1016/j.anaerobe.2021.102441 .
doi: 10.1016/j.anaerobe.2021.102441
pubmed: 34454094